Fefol Pregnancy®


ففول، مکمل زندگی

خانواده ففول، مکمل خانواده شماست



Fefol® Family

Innovation in Health, Commitment to Quality




Fefol Pregnancy®

Product Introduction

Fefol Pregnancy
is an advanced supplement, specifically formulated to meet the nutritional demands of pregnancy. With a balanced combination of iron, folic acid, vitamins, and other essential micronutrients, it supports the prevention and treatment of iron deficiency anemia, optimal fetal development, and maternal health during pregnancy.

Key Product Features:

- Simultaneous support for maternal and fetal health, meeting nutritional needs during pregnancy.
- Scientifically formulated with high tolerability and proven efficacy.
- Contains ferrous bisglycinate iron with up to 70% higher absorption compared to other iron forms.
- Helps rapidly increase ferritin and hemoglobin levels during pregnancy.
- Suitable for pregnant women with gastrointestinal issues or malabsorption disorders.
- Resistant to enzymatic and dietary inhibitors, ensuring superior absorption.
- Helps improve mood and reduce pregnancy–related depression
- Free from common gastrointestinal side effects such as constipation, metallic taste, bloating, and common pregnancy–related discomforts.
- Synergistic formulation enhances the absorption and efficacy of vitamins and nutrients.
- Contains iodine for fetal brain and nervous system development, and prevention of thyroid disorders.
- Equipped with Slow Release and Enteric Coated technology for optimal absorption and reduced food interactions.
- Contains proprietary Quatrefolic and folic acid with optimized absorption and a key role in the prevention of neural tube defects.



"Graph depicting changes in average hemoglobin concentration in pregnant women after 58 days of supplementation with ferrous bisglycinate (comparison of hemoglobin levels at the beginning and end of the study)."

Table 2. Comparison between hematological indices in the study groups at baseline visit and at 8 weeks after treatment.


	Group I (ferrous bis–glycinate) n = 93			Group II (ferrous glycine sulfate) n = 94			interGroup comparisons p–value	
Hematological indices	Baseline	After 8 weeks	p–value	Baseline	After 8 weeks	p–value	Baseline	After 8 weeks
HB (d/dL)	9.15 ± 0.61	11.63 ± 0.73	.001*	9.26 ±0.64	10.58 ± 0.82	.001*	.22	.000*
Hematocrit (%)	31.76 ± 2.06	36.26 ± 1.75	.001*	31.90 ± 2.31	34.43 ± 2.36	.001*	.65	.005*
MCV (fl)	78.06 ∓ 2.56	81.66 ∓ 2.64	.001*	77.68 ± 2.25	79.54 ± 2.85	.001*	.27	.000*
MCHC (d/dL)	28.46 + 1.76	32.95 + 1.62	.001*	28.53 ± 1.73	30.96 ± 1.89	.001*	.78	.000*
TIBC (µg/dL)	384.4 ± 53.22	269.2 ± 39.98	.001*	368.60 ± 52.8	316.60 ± 34.4	.001*	.06	.000*
Ferritin (µg/L)	11.09 ± 2.97	30.2 ± 4.54	.001*	11.20 ± 3.31	24.9 ± 4.48	.001*	.12	.000*


"Comparison of Hematologic Indices between Ferrous Bisglycinate and Ferrous Glycine Sulfate in Pregnant Women (at Baseline and 8 Weeks Post–Treatment)".

Table 3. Comparison between the adverse effects of both study medications.


	Group I (ferrous bis–glycinate) n = 93		Group II (ferrous glycine sulfate) n = 94		p–value
Adverse effects	N	%	N	%	
Constipation	12	12.9	27	28.7	
Nausea/vomiting	2	2.1	5	5.3	
Abdominal colic	3	3.2	3	3.2	
Diarrhea	2	2.1	3	3.2	.001*
Metallic taste in the mouth	1	1.1	1	1.1	
Black staining of the stool	1	1.1	1	1.1	
No adverse effects*	81	87.1	66	70.2	

Table Comparing the Side Effects of Ferrous Bisglycinate and Ferrous Glycine Sulfate in Pregnant Women (Clinical Study)







Evaluation of Changes in Hemoglobin and Serum Ferritin Over Three Months Following Administration of Iron in the Form of Ferrous Bisglycinate."



The corresponding chart illustrates the relative absorption of various iron compounds, clearly highlighting the difference in absorption between Ferrochel (iron in the form of ferrous bisglycinate) and other forms of iron.



The corresponding figure illustrates that Quatrefolic is directly converted into 5–methyltetrahydrofolate and is absorbed without the need for enzymatic conversion. In contrast, regular folic acid may not be properly metabolized in some pregnant women, especially those with MTHFR polymorphism, leading to the accumulation of unmetabolized folic acid (UMFA). This characteristic makes Quatrefolic a safe and effective choice during pregnancy.



The corresponding diagram demonstrates that Quatrefolic has significantly higher bioavailability compared to regular folic acid. This feature leads to faster absorption, increased efficacy, and a reduction in the accumulation of unmetabolized folic acid (UMFA) in pregnant women's bodies, which is crucial for maternal health and optimal fetal development.


Indications:

Fefol Pregnancy is a high–absorption specialized supplement designed to meet maternal and fetal nutritional needs during pregnancy.

Supplement Facts

Serving Size: 1 capsule
Servings Per Container: 30

	Amount Per Serving	% Daily Value
Vitamin A (as Palmitate)	4000 IU	50%
Vitamin C (as Ascorbic Acid)	110 mg	183%
Vitamin D3 (as Cholecalciferol)	400 IU	100%
Vitamin E (as DL-Alpha Tocopheryl Acetate)	13 IU	35%
Vitamin B1 (as Thiamine Mononitrate)	3 mg	176%
Vitamin B2 (as Riboflavin)	1.7 mg	85%
Niacin (as Niacinamide)	20 mg	100%
Vitamin B6 (as Pyridoxine HCl)	2.6 mg	104%
Iron (FERROCHEL® Ferrous Bisglycinate Chelate (27mg elemental Iron))	98.6 mg	150%
Folate (as 5-methyltetrahydrofolic acid, Quatrefolic®)	400 mcg	100%
Folic acid	400 mcg	100%
Vitamin B12 (as Cyanocobalamin)	4 mcg	50%
Biotin	150 mcg	50%
Pantothenic Acid	10 mg	100%
Iodine (as Potassium Iodine)	150 mcg	100%



Licensed by INTRAPHARM USA

References

Patanwala I et al. Folic acid handling by the human gut: implications for food fortification and supplementation. Am J Clin Nutr. 2014

Pietrzik K et al. Folic acid and L–5–methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2010

Wilcken B et al. Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas worldwide. J Med Genet. 2003

Suva, Manoj A., and Pravin R. Tirgar. "Comparative evaluation of different oral iron salts in the management of iron deficiency anemia." DARU Journal of Pharmaceutical Sciences (2024): 1–10.

Milman, N., Jønsson, L., Dyre, P., Pedersen, P. L., & Larsen, L. G. (2014). Ferrous bisglycinate 25 mg iron is as effective as ferrous sulfate 50 mg iron in the prophylaxis of iron deficiency and anemia during pregnancy in a randomized trial. Journal of perinatal medicine, 42(2), 197–206.

Abbas, A. M., Abdelbadee, S. A., Alanwar, A., & Mostafa, S. (2019). Efficacy of ferrous bis–glycinate versus ferrous glycine sulfate in the treatment of iron deficiency anemia with pregnancy: a randomized double–blind clinical trial. The Journal of Maternal–Fetal & Neonatal Medicine, 32(24), 4139–4145.

Raiturker, A. P. P., Ponnuswami, G., Shah, J. H., Patil, S. R., Daule, J. P., Chinda, M., & Jaiswal, A. (2023). Real–World Evaluation of Safety and Effectiveness of Ferrous Bis–Glycinate and Its Combination in Pregnant Women with Iron Deficiency Anemia. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 12(5), 1232–1236.

Fischer, J. A., Cherian, A. M., Bone, J. N., & Karakochuk, C. D. (2023). The effects of oral ferrous bisglycinate supplementation on hemoglobin and ferritin concentrations in adults and children: a systematic review and meta–analysis of randomized controlled trials. Nutrition reviews, 81(8), 904–920.


Fefol MAX® 100
30 Capsules
Polysaccharide - Iron Complex
Supplement
INTRAPHARM
Fefol Breastfeeding ®
30 Capsules
Supplement
INTRAPHARM
Fefol Plus ®
30 Capsules
INTRAPHARM
Fefol Pregnancy®
30 Capsules
Supplement
INTRAPHARM
Fefol GYNE®
30 Capsules
INTRAPHARM
Fefol DUODENAL®
30 Capsules
INTRAPHARM
Fefol Vitamins®
30 Capsules
Multi-Vitamin
Supplement
INTRAPHARM
Fefol® Sopnsule Capsules
30 Capsules
INTRAPHARM

Fefol® Family

Intrapharm.USA





OFOGH DAROU

داروسازی افق دارو

fefol.family

ofoghdarou.com

fefolfamily.com